Vaccines

16 Feb 2021 AstraZeneca COVID-19 vaccine authorised for emergency use by the World Health Organization
12 Feb 2021 ImmunityBio and NantKwest Announce FDA Authorization to Study hAd5 T-Cell COVID-19 Vaccine for Combination of Subcutaneous, Oral and Sublingual Boost to Induce T-Cell, Mucosal, and Antibody Immunity
12 Feb 2021 CureVac Initiates Rolling Submission With European Medicines Agency for COVID-19 Vaccine Candidate, CVnCoV
10 Feb 2021 AstraZeneca and IDT Biologika sign letter of intent to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity
08 Feb 2021 Sinovac Receives Conditional Marketing Authorization in China for its COVID-19 Vaccine
08 Feb 2021 COVAXX’s COVID-19 Vaccine, UB-612, Induced Neutralizing Antibodies in 100% of Participants During Phase 1 Clinical Trial
06 Feb 2021 Science Advances: Elicio Therapeutics’ SARS-CoV-2 Vaccine Demonstrates T Cell Responses >25 Fold Higher Than Benchmark Vaccines
06 Feb 2021 Sinovac Announces Phase III Results of Its COVID-19 Vaccine
05 Feb 2021 First-in-human clinical trial confirms novel HIV vaccine approach developed by IAVI and Scripps Research
05 Feb 2021 Novavax Announces Start of Rolling Review by Multiple Regulatory Authorities for COVID-19 Vaccine Authorization
05 Feb 2021 Johnson & Johnson Announces Submission of Application to the U.S. FDA for Emergency Use Authorization of its Investigational Single-Shot Janssen COVID-19 Vaccine Candidate
04 Feb 2021 Intrommune Receives IND Clearance From U.S. Food and Drug Administration for INT301
04 Feb 2021 Dynavax and Serum Institute of India Announce First Participant Dosed in a Phase 1 Clinical Trial Evaluating an Improved Tdap Vaccine Adjuvanted with CpG 1018
03 Feb 2021 Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
03 Feb 2021 GSK and CureVac to develop next generation mRNA COVID-19 vaccines
03 Feb 2021 COVAXX Announces Initiation of Phase 2 Clinical Trials in Taiwan of UB-612 Vaccine Candidate against COVID-19
03 Feb 2021 COVID-19 Vaccine AstraZeneca confirms 100% protection against severe disease, hospitalisation and death in the primary analysis of Phase III trials
01 Feb 2021 SQZ Biotechnologies Announces FDA Clearance of IND Application to Allow for Clinical Trial with SQZ Activating Antigen Carriers (SQZ AACs) in Patients with HPV+ Tumors
29 Jan 2021 Johnson & Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of its Phase 3 ENSEMBLE Trial
29 Jan 2021 COVID-19 Vaccine AstraZeneca recommended for use in the EU
29 Jan 2021 Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
28 Jan 2021 OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein
26 Jan 2021 Providence Therapeutics announces first subject has been dosed in COVID-19 vaccine trial
26 Jan 2021 Medigen Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan
25 Jan 2021 BioVaxys Announces Initiation of Cancer Vaccine EU Clinical Program, Completion of BVX-0320 Preclinical Program

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top